A randomized, placebo-controlled, phase III trial shows nivolumab can prolong median OS by 1 month (5.26 vs. 4.14 months) in PD-L1-positive (≥1%) advanced gastric cancer (21). This evidence concerns the gene CD274 and gastric cancer.